Clinical Scorecard: FDA Approves Expanded Liquid Biopsy Panel
At a Glance
| Category | Detail |
|---|---|
| Condition | Advanced Cancer |
| Key Mechanisms | Comprehensive molecular profiling through genomic and epigenomic analysis from a blood sample. |
| Target Population | Patients with advanced cancer, including those with non–small cell lung cancer, colorectal cancer, and advanced breast cancer with ESR1 mutations. |
| Care Setting | Applicable across multiple stages of cancer care, including treatment selection, recurrence monitoring, and cancer screening. |
Key Highlights
- Largest FDA-approved liquid biopsy panel with a genomic footprint 100 times broader than previous versions.
- Combines genomic and epigenomic profiling to enhance circulating tumor DNA detection sensitivity.
- Identifies clinically actionable findings not detectable through genomic analysis alone.
- Results available within 7 days and usable regardless of tissue availability.
- Covered by Medicare and commercial insurers for over 300 million lives.
Guideline-Based Recommendations
Diagnosis
- Utilize the Guardant360 Liquid CDx for comprehensive tumor profiling.
Management
- Support treatment selection for advanced cancer therapies, particularly in non–small cell lung cancer and colorectal cancer.
Monitoring & Follow-up
- Employ for recurrence monitoring and cancer screening.
Risks
- Consider the limitations of liquid biopsy in specific clinical scenarios.
Patient & Prescribing Data
Patients with advanced cancer, particularly those with specific mutations.
Facilitates targeted therapy selection and improves treatment outcomes.
Clinical Best Practices
- Incorporate liquid biopsy results into clinical decision-making.
- Use the assay in conjunction with other diagnostic tools for comprehensive care.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
